Investor Pitch Data: CODITECT WO Module
Date: 2026-02-13 | Classification: Confidential — Fundraising
Module: Autonomous Change Control for Regulated Bioscience
The One-Liner
CODITECT is the first AI-agent platform that makes change control autonomous for regulated bioscience — turning a 6-week manual compliance process into a 6-hour orchestrated workflow.
Problem (Pain Quantified)
| Pain Point | Current State | Data Point |
|---|---|---|
| Manual change control | 15–40 hours per change record | Industry benchmark: ~$2,500–$8,000 fully loaded cost per change |
| Compliance failures | 23% of FDA 483 observations cite inadequate change control | FDA FY2024 inspection data |
| Disconnected tools | Avg. bioscience QMS stack = 4.7 separate tools | Greenlight Guru/MasterControl customer surveys |
| Audit preparation | 80–120 hours per regulatory audit | Industry average for mid-market biotech |
| Vendor coordination | 30% of change cycle time is waiting on vendor documentation | WO system analysis (Appendix A scenario) |
| Agent-driven changes | 0 tools exist for AI agent change control | Competitive analysis — greenfield |
Cost of Inaction
A mid-market biotech (200 employees, 50 validated systems) processes ~200–400 change records/year:
| Metric | Manual Process | With CODITECT | Savings |
|---|---|---|---|
| Hours per change | 25 hrs avg | 4 hrs avg (84% automated) | 21 hrs |
| Annual change hours | 7,500 hrs | 1,200 hrs | 6,300 hrs |
| Fully loaded cost ($150/hr) | $1.125M | $180K | $945K/yr |
| Audit prep time | 100 hrs/audit × 2/yr | 15 hrs/audit × 2/yr | 170 hrs |
| 483 observation risk | 23% citation rate | <5% (structural compliance) | 78% reduction |
| Time-to-compliance for changes | 6 weeks avg | 5 days avg | 83% reduction |
ROI: $945K savings / $120K ACV = 7.9× first-year return
Solution
What CODITECT's WO Module Does
-
Autonomous Orchestration — AI agents decompose a Master Work Order into task-level Linked WOs, assign resources, schedule execution, and coordinate vendors — automatically.
-
Structural Compliance — Change control is database-enforced (append-only audit trails, immutable signatures, state machine guards), not policy-based. Agents cannot bypass compliance because the architecture prevents it.
-
Intelligent Routing — Model router selects Opus for compliance decisions, Sonnet for complex logic, Haiku for boilerplate — delivering 40–60% token cost reduction while maintaining audit-grade quality.
-
Hierarchical Change Control — Master/Linked WO hierarchy maps real-world change processes (e.g., Win10→Win11 lab upgrade = 1 Master + 6 Linked WOs with dependencies).
Technical Differentiators
| Capability | CODITECT | ServiceNow | Veeva QMS | MasterControl |
|---|---|---|---|---|
| AI agent orchestration | ✅ Native | ❌ None | ❌ None | ❌ None |
| Autonomous change decomposition | ✅ Agent-driven | ❌ Manual | ❌ Manual | ❌ Manual |
| Immutable audit trail | ✅ DB-enforced | ⚠️ Configurable | ✅ Yes | ✅ Yes |
| Multi-agent coordination | ✅ 7 agent types | ❌ None | ❌ None | ❌ None |
| 21 CFR Part 11 e-signatures | ✅ Native | ⚠️ Add-on | ✅ Native | ✅ Native |
| Work order hierarchy | ✅ Master/Linked DAG | ⚠️ Limited | ❌ None | ❌ None |
| Token cost optimization | ✅ Model routing | N/A | N/A | N/A |
| Vendor coordination portal | ✅ Agent-driven | ⚠️ Workflow | ❌ None | ❌ None |
Market Opportunity
| Metric | Value |
|---|---|
| TAM | $7.2B (2026) — QMS + WO + CMMS in regulated life sciences |
| SAM | $378M (2026) — Cloud-ready, mid-market, compliance-active, AI-adopting |
| SOM (Y5) | $26.25M ARR — 150 customers × $175K ACV |
| Market growth | 13.6% CAGR (biotech QMS segment) |
| Cloud adoption | 67% of QMS deployments (2025), growing |
| Change mgmt module growth | 13%+ CAGR — fastest QMS segment |
Beachhead: CDMOs (Contract Development & Manufacturing Organizations)
- Fastest growing QMS end-user at 17% CAGR
- Manage validated systems for multiple clients simultaneously
- Highest change volume per employee
- Most pain from disconnected tools (avg. 6.2 per CDMO)
- Regulatory compliance is existential — lose certification = lose business
Business Model
| Revenue Stream | Pricing | % of Revenue (Y3) |
|---|---|---|
| Platform fee (WO Engine) | $2,500/mo flat | 35% |
| Agent seat licenses | $150/seat/mo | 30% |
| Compliance module | $1,500/mo add-on | 15% |
| Professional services | Project-based | 15% |
| Success-based (audit pass) | Performance bonus | 5% |
Gross margin target: 78% (SaaS + AI compute costs offset by model routing optimization)
Unit Economics (Y3 Steady State)
| Metric | Target |
|---|---|
| ACV | $120K |
| CAC | $35K |
| LTV | $480K (4-year avg. life) |
| LTV:CAC | 13.7× |
| Payback period | 3.5 months |
| Net revenue retention | 125% (expansion from compliance + platform add-ons) |
| Gross margin | 78% |
Traction & Milestones
| Phase | Timeline | Milestone |
|---|---|---|
| Architecture (current) | Q1 2026 | Complete system design, ADRs, C4 model, compliance mapping |
| POC | Q2 2026 | Core WO lifecycle, audit trail, basic API — 1 design partner |
| Pilot | Q3 2026 | Resource matching, hierarchy/DAG, e-signatures, Vault — 3 design partners |
| Beta | Q4 2026 | Agent adapter, compliance engine, event bus, observability — 5 beta customers |
| GA | Q1 2027 | Production release, 3 paying customers |
| Growth | 2027–2028 | 12–35 customers, Series A fundraise |
Team Advantage
| Attribute | Relevance |
|---|---|
| 30+ years healthcare IT | Deep domain expertise in regulated environments |
| GRAIL Inc. (FDA Class II medical device) experience | First-hand 21 CFR Part 11 implementation |
| Google AI Accelerator participant | Access to AI/ML resources, mentorship, ecosystem |
| Serial entrepreneur track record | Proven ability to build and scale enterprise products |
| Full-stack architecture capability | CTO-led technical execution, no dependency on outsourced architecture |
Ask
| Item | Amount | Use |
|---|---|---|
| Pre-seed / Seed | $1.5–2.5M | 12-month runway: 2 engineers + 1 sales/BD + infrastructure + compliance certification |
| Key hires | 2 backend engineers (TypeScript/Python, regulated software experience) | |
| Milestones for next raise | 10 paying customers, $850K ARR, SOC 2 Type I certification |
Key Metrics to Track
| Category | Metric | Target |
|---|---|---|
| Product | WO cycle time reduction | >80% vs. manual baseline |
| Product | Compliance first-pass rate | >95% |
| Product | Agent task completion rate | >90% |
| Business | Customer acquisition | 3 design partners → 12 early adopters (Y2) |
| Business | ARR growth | $150K → $1M → $4.2M (Y1–Y3) |
| Business | Net revenue retention | >120% |
| Compliance | FDA 21 CFR Part 11 coverage | 100% by Q3 2026 |
| Compliance | SOC 2 Type I | Achieved by Q4 2026 |
| Technical | Token cost per WO | <$2.50 avg (via model routing) |
Copyright 2026 AZ1.AI Inc. All rights reserved. Developer: Hal Casteel, CEO/CTO Product: CODITECT-BIO-QMS | Part of the CODITECT Product Suite Classification: Internal - Confidential